Biodexa Pharmaceuticals (BDRX) Change in Account Payables (2013 - 2021)

Biodexa Pharmaceuticals (BDRX) has 4 years of Change in Account Payables data on file, last reported at $1.1 million in Q3 2021.

• For the quarter ending Q3 2021, Change in Account Payables rose 1201.69% year-over-year to $1.1 million; the trailing twelve-month figure through Sep 2021 stood at $1.3 million (changed N/A YoY), and the FY2025 full-year result was -$1.2 million, down 141.89% from the prior year.
• Change in Account Payables grew to $1.1 million in Q3 2021, from $91111.1 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $1.1 million in Q3 2021 to a low of -$55286.2 in Q4 2019.
• A 3-year average of $313439.0 and a median of $89000.7 in 2020 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables surged 264.8% in 2020 and jumped 1201.69% in 2021, its largest moves.
• Tracing BDRX's Change in Account Payables over 3 years: stood at -$55286.2 in 2019, then surged by 264.8% to $91111.1 in 2020, then soared by 1141.39% to $1.1 million in 2021.
• Business Quant data shows BDRX's Change in Account Payables at $1.1 million in Q3 2021, $91111.1 in Q4 2020, and $86890.3 in Q3 2020.